Antonio Palumbo.

Baseline features were well balanced among the procedure groups , except for an increased Karnofsky performance-status rating in the MP group than in the MPR and MPR-R groups. The median age was 71 years; 111 patients were older than 75 years. A higher proportion of patients had International Staging Program stage III disease . The median duration of follow-up was 30 weeks . Efficacy Progression-free survival was the principal end point. MPR-R significantly prolonged progression-free survival as compared with MPR and MP ; the MPR and MP groups did not differ significantly with respect to progression-free survival . In a prespecified landmark analysis, lenalidomide maintenance significantly expanded progression-free survival right away of maintenance therapy in comparison with placebo .I am honored we are able to identify her with this award. Obama signaled a renewed U.S. Dedication to funding for global AIDS programs at a time when resources in the home are constrained and additional countries are backing from the fight, he writes, adding, Now you have to plot a course for applying the president’s eyesight. Related StoriesUsing the butterfly impact to predict heart disease: an interview with Dr George and Dr Parthimos, Cardiff UniversityClinical trial suggests HIV individuals should begin therapy sooner instead of laterVoice cloning: an interview with Paul Welham, CEO, CereProcCollins outlines a true number of approaches for meeting these targets, and writes, Four factors are critical to success and deserve immediate attention: strategic decision-making, increased financing, balancing global targets with focus on the most vulnerable, and research.